Citigroup
TXG icon

Citigroup’s 10x Genomics TXG Stock Holding History

Citigroup’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.58M Buy
67,385
+16,910
+34% +$443K ﹤0.01% 2736
2026
Q1 		$1.07M Sell
50,475
-85,480
-63% -$1.71M ﹤0.01% 3074
2025
Q4 		$2.22M Sell
135,955
-125,368
-48% -$1.89M ﹤0.01% 2588
2025
Q3 		$3.05M Buy
261,323
+93,104
+55% +$1.21M ﹤0.01% 2337
2025
Q2 		$1.95M Buy
168,219
+84,275
+100% +$768K ﹤0.01% 2673
2025
Q1 		$733K Sell
83,944
-35,031
-29% -$442K ﹤0.01% 3456
2024
Q4 		$1.71M Buy
118,975
+103,089
+649% +$1.63M ﹤0.01% 2943
2024
Q3 		$359K Sell
15,886
-8,048
-34% -$166K ﹤0.01% 3946
2024
Q2 		$466K Buy
23,934
+11,395
+91% +$298K ﹤0.01% 3441
2024
Q1 		$471K Sell
12,539
-36,699
-75% -$1.61M ﹤0.01% 3618
2023
Q4 		$2.76M Buy
49,238
+38,287
+350% +$1.67M ﹤0.01% 1988
2023
Q3 		$452K Buy
10,951
+5,317
+94% +$277K ﹤0.01% 3137
2023
Q2 		$315K Buy
5,634
+552
+11% +$29.9K ﹤0.01% 3656
2023
Q1 		$284K Sell
5,082
-16,137
-76% -$754K ﹤0.01% 3533
2022
Q4 		$773K Sell
21,219
-5,313
-20% -$174K ﹤0.01% 2852
2022
Q3 		$755K Sell
26,532
-15,920
-38% -$607K ﹤0.01% 2935
2022
Q2 		$1.92M Sell
42,452
-25,065
-37% -$1.3M ﹤0.01% 2133
2022
Q1 		$5.14M Buy
67,517
+1,388
+2% +$121K ﹤0.01% 1655
2021
Q4 		$9.85M Sell
66,129
-5,467
-8% -$837K 0.01% 1390
2021
Q3 		$10.4M Sell
71,596
-20,665
-22% -$3.55M 0.01% 1382
2021
Q2 		$18.1M Buy
92,261
+18,372
+25% +$3.32M 0.01% 1060
2021
Q1 		$13.4M Buy
73,889
+3,011
+4% +$520K 0.01% 1188
2020
Q4 		$10M Buy
70,878
+21,725
+44% +$3.15M 0.01% 1547
2020
Q3 		$6.13M Buy
49,153
+45,473
+1,236% +$4.77M ﹤0.01% 1764
2020
Q2 		$329K Buy
3,680
+2,912
+379% +$227K ﹤0.01% 4620
2020
Q1 		$48K Buy
768
+268
+54% +$20.9K ﹤0.01% 6002
2019
Q4 		$38K Buy
+500
New +$30.1K ﹤0.01% 6541

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup's TXG Position: Q2 2026 in Review

Citigroup increased its 10x Genomics (TXG) stake by 34% in Q2 2026, buying an estimated $443K and bringing the position to 67,385 shares worth $2.58M. The position accounts for ﹤0.01% of the portfolio, ranked #2736.

Citigroup first reported a position in TXG in Q4 2019 and has held it in 27 quarters since. The position peaked at $18.1M in Q2 2021. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Citigroup held 67,385 shares of 10x Genomics worth $2.58M as of Q2 2026.
  • Citigroup bought 16,910 10x Genomics shares in Q2 2026, an estimated $443K.
  • 10x Genomics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2736 holding.
  • Citigroup first reported a position in 10x Genomics in Q4 2019 and has held it in 27 quarters since.
  • Citigroup's 10x Genomics position peaked at $18.1M in Q2 2021.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.